{"id":"W2229928017","doi":"","title":"進行・再発の薬物療法Pertuzumab（パージェタ(R)）を用いた進行乳癌症例2 Trastuzumab＋Pertuzumab＋Eribulin（3rd line）（臨床報告）","year":2014,"lang":"ja","type":"article","venue":"Pharma Medica","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"","keywords":"Pertuzumab; Eribulin; Trastuzumab; Medicine; Internal medicine; Metastatic breast cancer; Cancer; Breast cancer","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.001899142,0.001522079,0.00226963,0.0007668184,0.0009989393,0.0002344054,0.001231731,0.0007893926,0.03174694],"category_scores_gemma":[0.003215428,0.001371586,0.001129805,0.001205242,0.0008180116,0.0005688971,0.0004013742,0.003088349,0.007208549],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009549301,"about_ca_system_score_gemma":0.001192855,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005401959,"about_ca_topic_score_gemma":0.00003976304,"domain_scores_codex":[0.9903068,0.0006565734,0.002461691,0.001956163,0.002291774,0.00232698],"domain_scores_gemma":[0.9925153,0.001416698,0.0008108987,0.001888918,0.0007345632,0.002633571],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.002155354,0.004699981,0.0006423892,0.001646822,0.002559276,0.0009080967,0.008276915,0.0001962334,0.2781817,0.001083096,0.4050554,0.2945947],"study_design_scores_gemma":[0.009349534,0.002980149,0.0004732215,0.002245079,0.001802333,0.0008306122,0.001056614,0.06027674,0.05310169,0.000141656,0.866201,0.001541352],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5953931,0.03008309,0.02483543,0.09086548,0.05551241,0.006459903,0.001507722,0.003822522,0.1915203],"genre_scores_gemma":[0.9604374,0.003222929,0.00049815,0.01104007,0.01488896,0.0001953531,0.0005326442,0.0003695786,0.00881487],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4611456,"threshold_uncertainty_score":0.9997528,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03585227091159457,"score_gpt":0.316730037660179,"score_spread":0.2808777667485844,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}